Home › Tag Archives › percent

Wedding Bells Still Chime

If you believe marriage is in decline, think again. A new government report has found that 8 in 10 women will get married by the time they turn 40, a figure that is virtually unchanged from the 1990s, before the drop in middle-income jobs reduced the supply of marriageable men.

The report was based on findings from the National Survey of Family Growth, a survey of more than 22,000 men and women conducted by the Centers for Disease Control and Prevention between 2006 and 2010. It provides one of the best estimates for marriage and divorce in the United States, and drew considerable attention among researchers and news organizations when it was released publicly on Thursday.

But while many chose to highlight the most immediate finding, that 4 in 10 women between the ages of 15 and 44 are currently married, demographers who sifted through the numbers said the longer-term trend ? that most women eventually still do marry ? was more surprising, as it challenged the now commonly held perception that marriage is disappearing.

?The idea that marriage is on the decline and fading away, that picture is misleading,? said Andrew Cherlin, a demographer at Johns Hopkins University.

Lifetime marriage is far lower today than it was during the peak years in the 1950s, when more than nine-tenths of the adult population married at some point in their lives. But the new report suggests that the decline may have stopped in recent decades, Mr. Cherlin said, as lifetime marriage rates have changed little since the 1990s.

The figure of 4 in 10 women currently married may seem stark, demographers say, but it is simply a reflection of the fact that women are marrying later in the age spectrum. (The survey questioned men and women ages 15 to 44.) In 1982, the share of women currently married was 52 percent, and in 1995 it was 49 percent.

The story, Mr. Cherlin said, is more about postponement than abandonment. Marriage has declined precipitously among young women, both college graduates and women with less education. But most women do eventually marry. According to the report, 82 percent of women who ended their formal education after graduating from high school will marry by the age of 40. Among women with a college degree the figure is 89 percent.

Marriage has remained mostly intact, but childbearing in wedlock has not, a change that has opened a deep class divide. College-educated women tend to wait to marry before having their children. Less educated women do not, a choice that has driven a major change in American family structure. More than half of all births to women under 30 take place outside of marriage, according to Child Trends, a research group in Washington.

Just 8 percent of births to women over 18 with a college degree happen outside wedlock, compared to 57 percent of births to women with high school diplomas or less, according to Child Trends, which cited 2009 data.

Source: http://economix.blogs.nytimes.com/2012/03/23/wedding-bells-still-chime/

dippin dots triumph the insult comic dog tucson weather tucson weather cl p cl p andy rooney

Wall Street focused on jobs, events in Europe

By msnbc.com news services

Wall Street is set for a higher open Friday as investors digest the?latest report on the U.S. labor market.

The Labor Department said Friday that U.S. employers added 80,000 jobs last month, while the nation’s lofty jobless rate ticked down to 9 percent in October, after holding at 9.1 percent for the previous three months.

Corporate news is another focus, insurer American International Group third-quarter results missed expectations following an impairment charge in its aircraft leasing unit.

Starbucks Corp’s quarterly profit beat expectations following strong global sales at cafes.

Troubled brokerage MF Global announced the resignation of its CEO John Corzine Friday. A sale is expected to be agreed by the end of the weekend of the bankrupt company?s operations in Asia and Australia after the provisional liquidator for the brokerage’s Hong Kong received nearly 40 credible offers.

PepsiCo Inc beverage subsidiary in China is being sold in China to an unlisted unit of instant noodle and drinks maker Tingyi Holdings Corp, a source with direct knowledge of the matter said.

Groupon Inc has raised $700 million in an initial public offering, making it the largest IPO by an Internet company since Google in 2004.

Banks will also be in the spotlight, the Wall Street Journal reported, citing people familiar with the matter, that the Bank of New York Mellon Corp is in talks with federal prosecutors over a currency lawsuit which accuses the bank of overcharging clients.

The White House said U.S. banks exposure to the euro zone crisis is modest and the United States can cope if the region’s debt crisis grows worse as worries intensify about Greece.

European shares rose on Friday on hopes a proposed referendum in Greece on a new bailout package which could threaten its membership in the euros would be avoided, easing concerns about a Greek default.

U.S. stocks rallied on Thursday, also on hopes the referendum would be called off, with the Dow Jones industrial average was up 1.8 percent, the Standard & Poor’s 500 Index gained 1.9 percent and the Nasdaq Composite Index rose 2.2 percent.

The Associated Press and Reuters contributed to this report.

Source: http://bottomline.msnbc.msn.com/_news/2011/11/04/8631661-wall-street-focused-on-jobs-events-in-europe

brewers harbaugh the walking dead season 2 milwaukee brewers will power will power indy 500

Cigna to buy Medicare co HealthSpring for $3.8 billion (Reuters)

(Reuters) ? Health insurer Cigna Corp will buy HealthSpring Inc for $3.8 billion to jump-start its business selling Medicare plans as more elderly Americans become eligible for the U.S. government program.

Medicare is an enticing market for U.S. health insurers, even as Congress weighs cuts to the program to rein in the country’s debt.

In particular, the entry of the postwar baby boom generation into retirement is expected to swell the ranks of privately run Medicare Advantage plans, which now account for 25 percent of Medicare enrollment, compared with 75 percent for government-run plans. Medicare beneficiaries can choose to receive their benefits through private health insurance plans.

“The expectation is that that 25 percent rate will increase,” Jefferies & Co analyst David Windley said. “There’s some increasing view that the political pendulum has swung in favor of Medicare Advantage plans in recognition that they are the one group out there doing something to reduce Medicare costs.”

Wedbush Securities analyst Sarah James projects private insurance plans could comprise about half of Medicare over the next five years.

Medicare contractors receive payments from the government and then market their plans directly to seniors. Compared to government-run plans, they have narrower networks of physicians that allow them to keep their costs lower. The companies also try to limit medical claims by driving members to seek preventive care so they avoid costly hospitalizations.

“The basic proposition to the beneficiary has always been … by going into a narrower network, we will provide you with richer benefits,” said John Gorman, head of the Gorman Health Group, a consulting firm focused on government-sponsored plans.

UnitedHealth Group Inc and Humana Inc are the largest private players in Medicare Advantage, with 2.2 million and 1.6 million members respectively. Large insurers WellPoint Inc and Aetna Inc have also struck deals to expand their presence in Medicare, but Cigna’s purchase of HealthSpring is by far the biggest single bet.

(For a graphic on major health insurance deals, see: http://link.reuters.com/sak64s.)

HealthSpring has about 340,000 Medicare Advantage members in 11 states and the District of Columbia, making it the sixth-biggest player, according to Susquehanna Financial Group analyst Chris Rigg. Cigna has 46,000 Medicare Advantage members. HealthSpring also has more than 800,000 enrollees in stand-alone Medicare prescription drug plans.

CIGNA CEO MOVES TO DIVERSIFY

The deal represents a major diversification for Cigna and the most significant move by Chief Executive David Cordani since he took the helm nearly two years ago. Cigna had focused its U.S. health insurance plans on businesses, though Cordani sought more international expansion.

While overall merger activity has slowed in the last few months, transactions such as the HealthSpring buy are happening as companies look to expand into new businesses or cut costs.

Recent deals include Kinder Morgan’s $21 billion deal for El Paso Corp and Google’s planned $12.5 billion buy of Motorola Mobility Holdings Inc.

Cigna plans to buy HealthSpring for $55 a share, a 37 percent premium over Friday’s closing price, the companies said in a statement on Monday. HealthSpring shares closed up 33.7 percent at $53.71, while Cigna rose 1.4 percent to $45.34.

Cigna said it would issue new equity to cover about 20 percent of the purchase price, with the rest funded by additional debt and cash. It expects the deal to add to its earnings per share in the first full year of operations.

Shares of other health insurers that specialize in Medicare rose after the deal was announced. Humana rose 4.7 percent, Universal American Corp gained 3.9 percent, and WellCare Health Plans jumped 8.8 percent.

“There are still a few larger plans in the industry that want to become bigger Medicare players, and the number of plans out there … with more than 50,000 lives is relatively small,” Citigroup analyst Carl McDonald said in a research note.

Shares of Canadian pharmacy benefit manager SXC Health Solutions Corp, which counts HealthSpring as a major client, fell 23 percent on fears the business may go to Cigna.

Investors have expected consolidation in the health insurance industry as a U.S. healthcare overhaul enacted last year squeezes smaller companies and creates incentives for larger companies to take advantage of scale.

The lack of major deals to date may stem from concerns that the Obama administration and state insurance regulators could push back against transactions that threaten competition or drive premiums higher.

Asked whether the HealthSpring deal would face regulatory hurdles, Cordani told reporters on a conference call that it was a “segment expansion” into an area where the company is not a large player and therefore should not meet opposition.

“It’s not a scale-based consolidation,” Cordani said. “We’re obviously aware of the environment around scale-based consolidation.”

The deal is expected to close in the first half of 2012.

MEDICARE MORE VALUABLE

The deal values HealthSpring at a “relatively rich” $3,200 per member, compared with the current industry average of about $869, Wells Fargo analyst Peter Costa said.

Medicare Advantage members bring in about three times as much revenue as commercial members, according to Susquehanna’s Rigg. Because Medicare members are older, they typically have more need to see doctors and pay higher premiums than younger people who receive insurance through their employers.

“The person who is 70 years old uses a lot more healthcare,” Rigg said. “It’s lower margins, but higher overall dollars.”

Profit margins for Medicare Advantage plans tend to range from 3 percent to 5 percent, Gorman said.

HealthSpring’s management, headed by CEO Herb Fritch, will now lead Cigna’s Medicare expansion.

Separately, Cigna raised its forecast for 2011 adjusted earnings to a range of $5.05 to $5.30 per share from a previous view of $4.95 to $5.25.

Cigna’s financial adviser is Morgan Stanley and its legal adviser is Davis Polk. Moelis & Co advised on the deal financing. Goldman Sachs & Co was the financial adviser to HealthSpring, whose legal advisers were Skadden, Arps, Slate, Meagher & Flom LLP and Bass, Berry & Sims Plc.

(Reporting by Lewis Krauskopf in New York; additional reporting by Toni Clarke in Boston; Editing by Michele Gershberg, John Wallace and Tim Dobbyn)

Source: http://us.rd.yahoo.com/dailynews/rss/seniors/*http%3A//news.yahoo.com/s/nm/20111024/hl_nm/us_cigna_healthspring

pearl jam 20 martha marcy may marlene lacuna lacuna paranormal activity 3 trailer paranormal activity 3 trailer oomph

Biogen MS trial data robust; shares jump (Reuters)

(Reuters) ? Full data from a late-stage clinical trial of Biogen Idec Inc’s experimental multiple sclerosis drug, BG-12, showed robust results across multiple measures and revealed no new safety concerns.

The news sent the biotech company’s shares soaring as much as 6.7 percent on Friday.

Earlier this year the company released initial data from the trial, known as DEFINE, which showed the drug, when given twice a day, cut the annualized relapse rate by 53 percent at two years compared with placebo, and cut the rate of disability progression by 38 percent.

Full data from the trial was presented on Friday at a meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and showed the drug reduced the risk of relapse by 49 percent in patients who took it twice a day and 50 percent in patients who took it three times a day.

“BG-12 may be a valuable treatment option for MS patients, combining strong efficacy, a favorable safety profile and oral administration,” said Dr. Ralf Gold, a trial investigator and professor at St. Josef-Hospital/Ruhr-University in Bochum, Germany. “Preclinical research has shown that BG-12 has anti-inflammatory and neuroprotective effects.”

Multiple sclerosis is a chronic, often disabling disease that attacks the central nervous system and can lead to numbness, loss of vision and paralysis. BG-12 is designed to treat relapsing-remitting MS, in which flare-ups are followed by periods of remission. About 85 percent of people with MS are initially diagnosed with this form of the disease.

Gold said that if the clinical responses seen in DEFINE are replicated later this year in a second late-stage trial known as CONFIRM, then “BG-12 has the potential to provide a new approach to treating MS and be an important step forward for patients.”

Magnetic resonance imaging (MRI) scans showed that at two years, patients receiving BG-12 experienced significant reduction in the number of brain lesions compared to patients on placebo.

“Coming out of Dr. Gold’s presentation, BG12′s clinical profile remains competitive with efficacy at the upper end of the range for all oral MS therapies,” said Geoff Meacham, an analyst at J.P. Morgan, in a research note. “Importantly, there were no new safety concerns in the data presented, removing a major risk, and the immediate feedback from neurologists at the session was positive.”

Adverse reactions were reported by 95 to 96 percent of patients, whether in the placebo group or treatment group. The most frequently reported events were flushing, MS relapse, nasopharyngitis, headache, diarrhea and fatigue. There were no deaths related to study treatment. There was no increase in infections, serious infections, opportunistic infections or malignancies, data showed.

Thomas Wei, an analyst at Jefferies & Company, said the data show that continued dosing of BG-12 beyond six months strengthens efficacy benefit, giving him increased confidence that the efficacy in DEFINE “will likely be replicated in

CONFIRM.”

The improvement in results with longer treatment likely explains why results from the two-year-long Phase III trial were significantly better than the six-month-long Phase II trial.

“BG-12 is clearly the trend of ECTRIMS 2011,” said Geoff Porges, an analyst at Sanford Bernstein. “The sentiment is very positive and every physician that we spoke to repeated the same phrase: “If the CONFIRM data is as strong as DEFINE, this drug will be the best selling drug in MS in a few years.”

Shares of Weston, Massachusetts-based Biogen were up 5.7 percent at $107.48 in mid-morning trading on Nasdaq after rising as high as $108.46 earlier in the session.

(Reporting by Toni Clarke, editing by Bernard Orr, Dave Zimmerman)

Source: http://us.rd.yahoo.com/dailynews/rss/biotech/*http%3A//news.yahoo.com/s/nm/20111021/hl_nm/us_biogen_ms

aron ralston grandparents day 911 9/11 ground zero world trade center university of michigan